A randomized trial comparing the diagnostic accuracy of visual inspection with acetic acid to Visual Inspection with Lugol's Iodine for cervical cancer screening in HIV-infected women

Megan J Huchko, Jennifer Sneden, Jennifer M Zakaras, Karen Smith-McCune, George Sawaya, May Maloba, Elizabeth Ann Bukusi, Craig R Cohen, Megan J Huchko, Jennifer Sneden, Jennifer M Zakaras, Karen Smith-McCune, George Sawaya, May Maloba, Elizabeth Ann Bukusi, Craig R Cohen

Abstract

Visual inspection with Acetic Acid (VIA) and Visual Inspection with Lugol’s Iodine (VILI) are increasingly recommended in various cervical cancer screening protocols in low-resource settings. Although VIA is more widely used, VILI has been advocated as an easier and more specific screening test. VILI has not been well-validated as a stand-alone screening test, compared to VIA or validated for use in HIV-infected women. We carried out a randomized clinical trial to compare the diagnostic accuracy of VIA and VILI among HIV-infected women. Women attending the Family AIDS Care and Education Services (FACES) clinic in western Kenya were enrolled and randomized to undergo either VIA or VILI with colposcopy. Lesions suspicious for cervical intraepithelial neoplasia 2 or greater (CIN2+) were biopsied. Between October 2011 and June 2012, 654 were randomized to undergo VIA or VILI. The test positivity rates were 26.2% for VIA and 30.6% for VILI (p = 0.22). The rate of detection of CIN2+ was 7.7% in the VIA arm and 11.5% in the VILI arm (p = 0.10). There was no significant difference in the diagnostic performance of VIA and VILI for the detection of CIN2+. Sensitivity and specificity were 84.0% and 78.6%, respectively, for VIA and 84.2% and 76.4% for VILI. The positive and negative predictive values were 24.7% and 98.3% for VIA, and 31.7% and 97.4% for VILI. Among women with CD4+ count < 350, VILI had a significantly decreased specificity (66.2%) compared to VIA in the same group (83.9%, p = 0.02) and compared to VILI performed among women with CD4+ count ≥ 350 (79.7%, p = 0.02). VIA and VILI had similar diagnostic accuracy and rates of CIN2+ detection among HIV-infected women.

Trial registration: ClinicalTrials.gov NCT02237326.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flowsheet of enrollment, randomization and…
Fig 1. Flowsheet of enrollment, randomization and screening results for VIA and VILI.

References

    1. Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Cosano R, et al. (2014) Human Papillomavirus and Related Diseases in Kenya. Summary Report 2014–03–17.
    1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, et al. (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010. Available: . Accessed 2013 December 21.
    1. Adefuye PO, Broutet NJ, de Sanjose S, Denny LA (2013) Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa. Vaccine 31 Suppl 5: F53–59. 10.1016/j.vaccine.2012.06.070
    1. Ezechi OC, Ostergren PO, Nwaokorie FO, Ujah IA, Odberg Pettersson K (2014) The burden, distribution and risk factors for cervical oncogenic human papilloma virus infection in HIV positive Nigerian women. Virology journal 11: 5 10.1186/1743-422X-11-5
    1. Franceschi S, Jaffe H (2007) Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 45: 510–513.
    1. Sherris J, Wittet S, Kleine A, Sellors J, Luciani S, et al. (2009) Evidence-based, alternative cervical cancer screening approaches in low-resource settings. International perspectives on sexual and reproductive health 35: 147–154. 10.1363/ifpp.35.147.09
    1. (2013) WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention Geneva: World Health Organization.
    1. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, et al. (2009) HPV screening for cervical cancer in rural India. The New England journal of medicine 360: 1385–1394. 10.1056/NEJMoa0808516
    1. Belinson JL, Pretorius RG, Zhang WH, Wu LY, Qiao YL, et al. (2001) Cervical cancer screening by simple visual inspection after acetic acid. Obstetrics and Gynecology 98: 441–444.
    1. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, et al. (2005) Cost-effectiveness of cervical-cancer screening in five developing countries. N Eng J Med 353: 2158–2168.
    1. Wright TC Jr., Denny L, Kuhn L, Goldie S (2002) Use of visual screening methods for cervical cancer screening. Obstetrics and gynecology clinics of North America 29: 701–734.
    1. Ghosh P, Gandhi G, Kochhar PK, Zutshi V, Batra S (2012) Visual inspection of cervix with Lugol's iodine for early detection of premalignant & malignant lesions of cervix. The Indian journal of medical research 136: 265–271.
    1. Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, et al. (2004) Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. International journal of cancer Journal international du cancer 110: 907–913.
    1. Consul S, Agrawal A, Sharma H, Bansal A, Gutch M, et al. (2012) Comparative study of effectiveness of Pap smear versus visual inspection with acetic acid and visual inspection with Lugol's iodine for mass screening of premalignant and malignant lesion of cervix. Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology 33: 161–165.
    1. Lewis KC, Tsu VD, Dawa A, Kidula NA, Chami IN, et al. (2011) A comparison of triage methods for Kenyan women who screen positive for cervical intraepithelial neoplasia by visual inspection of the cervix with acetic acid. African health sciences 11: 362–369.
    1. Bradford L, Goodman A (2013) Cervical cancer screening and prevention in low-resource settings. Clinical Obstetrics and Gynecology 56: 76–87. 10.1097/GRF.0b013e31828237ac
    1. Sankaranarayanan R, Wesley R, Thara S, Dhakad N, Chandralekha B, et al. (2003) Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India. International journal of cancer Journal international du cancer 106: 404–408.
    1. Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, et al. (2005) Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bulletin of the World Health Organization 83: 186–194.
    1. Cervical Cancer Action. Progress in cervical cancer prevention: The CCA report card. 2012. Available: . Accessed 2014 June.
    1. Sankaranarayanan R, Nessa A, Esmy PO, Dangou JM (2012) Visual inspection methods for cervical cancer prevention. Best practice & research Clinical obstetrics & gynaecology 26: 221–232.
    1. Ngoma T, Muwonge R, Mwaiselage J, Kawegere J, Bukori P, et al. (2010) Evaluation of cervical visual inspection screening in Dar es Salaam, Tanzania. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 109: 100–104. 10.1016/j.ijgo.2009.11.025
    1. Muwonge R, Manuel Mda G, Filipe AP, Dumas JB, Frank MR, et al. (2010) Visual screening for early detection of cervical neoplasia in Angola. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 111: 68–72. 10.1016/j.ijgo.2010.04.024
    1. Maiman M, Fruchter RG, Sedlis A, Feldman J, Chen P, et al. (1998) Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecologic Oncology 68: 233–239.
    1. World Health Organization (2007) Training modules for the syndromic management of sexually transmitted infections. Geneva.
    1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO Classification of Tumours of Female Reproductive Organs. Fourth Edition; IARC, editor. Geneva: IARC; 307 p.
    1. Huchko MJ, Bukusi EA, Cohen CR (2011) Building capacity for cervical cancer screening in outpatient HIV clinics in the Nyanza province of western Kenya. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 114: 106–110. 10.1016/j.ijgo.2011.02.009
    1. De Vuyst H, Claeys P, Njiru S, Muchiri L, Steyaert S, et al. (2005) Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 89: 120–126.
    1. Sahasrabuddhe VV, Bhosale RA, Kavatkar AN, Nagwanshi CA, Joshi SN, et al. (2012) Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India. International journal of cancer Journal international du cancer 130: 234–240. 10.1002/ijc.25971
    1. Joshi S, Sankaranarayanan R, Muwonge R, Kulkarni V, Somanathan T, et al. (2013) Screening of cervical neoplasia in HIV-infected women in India. AIDS 27: 607–615. 10.1097/QAD.0b013e32835b1041
    1. Firnhaber C, Mayisela N, Mao L, Williams S, Swarts A, et al. (2013) Validation of Cervical Cancer Screening Methods in HIV Positive Women from Johannesburg South Africa. PloS one 8: e53494 10.1371/journal.pone.0053494
    1. Chung MH, McKenzie KP, De Vuyst H, Richardson BA, Rana F, et al. (2013) Comparing pap smear, via, and hpv cervical cancer screening methods among hiv-positive women by immune status and antiretroviral therapy. AIDS.
    1. (2012) Prevention of cervical cancer through screening using visual inspection with acetic acid (VIA) and treatment with cryotherapy A demonstration project in six African countries: Malawi, Madagascar, Nigeria, Uganda, the United Republic of Tanzania and Zambia. Geneva: World Health Organization.
    1. Kenya Ministry of Health and Sanitation and Ministry of Medical Services (2011) National Cervical Cancer Prevention Program Action Plan: 2011–2015. Nairobi.
    1. Pretorius RG, Belinson JL, Azizi F, Peterson PC, Belinson S (2012) Utility of random cervical biopsy and endocervical curettage in a low-risk population. Journal of lower genital tract disease 16: 333–338. 10.1097/LGT.0b013e3182480c18
    1. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, et al. (2004) Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. American Journal of Obstetrics and Gynecology 191: 430–434.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren